{"ticker": {"uuid": "7f2a59b3-61e1-4395-90a3-19d622b51fe0", "symbol": "ZVRA", "name": "Zevra Therapeutics Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call", "summary": "Zevra Therapeutics announced it will report its second-quarter 2026 corporate and financial results on Wednesday, August 5, 2026, via a news release after market close. The company will also host a conference call and audio webcast at 4:30 p.m. ET on the same day. Details for acc", "url": "https://www.manilatimes.net/2026/07/22/tmt-newswire/globenewswire/zevra-therapeutics-announces-details-for-q2-2026-financial-results-call/2389262/amp", "source_name": "The Manila Times", "published_at": "2026-07-22T11:40:00", "published_display": "22 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra\u2019s Aug. 5 results webcast will be replayed for 90 days", "summary": "Zevra Therapeutics (NasdaqGS: ZVRA) announced it will release its Q2 2026 corporate and financial results on Wednesday, August 5, 2026, after market close, followed by a conference call and audio webcast at 4:30 p.m. ET. A replay of the webcast will be available for 90 days on th", "url": "https://www.stocktitan.net/news/ZVRA/zevra-therapeutics-announces-details-for-q2-2026-financial-results-600bgnmt0b0w.html", "source_name": "Stock Titan", "published_at": "2026-07-22T11:40:00", "published_display": "22 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics Announces Date for Second Quarter 2026 Financial Results Conference Call", "summary": "Zevra Therapeutics announced it will release its second quarter 2026 corporate and financial results on August 5, 2026, followed by a conference call and audio webcast at 4:30 p.m. ET. The company, which focuses on developing therapies for rare diseases, highlighted its commitmen", "url": "https://www.quiverquant.com/news/Zevra+Therapeutics+Announces+Date+for+Second+Quarter+2026+Financial+Results+Conference+Call", "source_name": "Quiver Quantitative", "published_at": "2026-07-22T11:40:00", "published_display": "22 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZVRA - Zevra Therapeutics: Galloping Through a Green Safari", "summary": "Zevra Therapeutics has successfully transitioned from a prodrug company to a rare disease powerhouse, marked by the FDA approval of MIPLYFFA for Niemann-Pick disease Type C and a $100 million sale of a Rare Pediatric Disease Priority Review Voucher. The company's financial standi", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-zvra/zevra-therapeutics/a4vhnswa-zevra-therapeutics-galloping-through-a-green-safari", "source_name": "Simply Wall Street", "published_at": "2026-07-20T15:11:30", "published_display": "20 Jul 2026 15:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "(ZVRA) as a Liquidity Pulse for Institutional Tactics", "summary": "This article provides an AI-driven analysis of Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting conflicting sentiment across different time horizons and suggesting potential choppy conditions. It presents three institutional trading strategies\u2014Position Trading, Momentum Break", "url": "https://news.stocktradersdaily.com/news_release/17/ZVRA_as_a_Liquidity_Pulse_for_Institutional_Tactics_071326014002_1783921202.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T01:40:00", "published_display": "13 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Zevra\u2019s Broad Russell Index Inclusion Reshaping the Investment Case for Zevra Therapeutics (ZVRA)?", "summary": "Zevra Therapeutics (ZVRA) has been added to several Russell indexes, including the Russell 2000 Value, increasing its visibility among institutional investors. While this inclusion may boost liquidity and trading support, it doesn't alter the fundamental product or regulatory ris", "url": "https://www.sahmcapital.com/news/content/is-zevras-broad-russell-index-inclusion-reshaping-the-investment-case-for-zevra-therapeutics-zvra-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T00:09:28", "published_display": "11 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics (ZVRA) Q4 2024 earnings summary", "summary": "Zevra Therapeutics (ZVRA) reported its Q4 2024 earnings, highlighting its transition to a commercial-stage company with the FDA approval and launch of Miplyffa for Niemann-Pick disease type C. The company achieved $23.6M in net revenue for FY 2024, driven by Miplyffa and OLPRUVA ", "url": "https://quartr.com/events/zevra-therapeutics-zvra-q4-2024_oCqDlg9E", "source_name": "Quartr", "published_at": "2026-07-10T12:12:06", "published_display": "10 Jul 2026 12:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics (ZVRA) Guggenheim Securities Inaugural Healthcare Innovation Conference summary", "summary": "Zevra Therapeutics (ZVRA) presented at the Guggenheim Securities Inaugural Healthcare Innovation Conference, highlighting its rare disease focus, two marketed products (MIPLYFFA and OLPRUVA), and late-stage development programs. The company discussed its commercial launch strateg", "url": "https://quartr.com/events/zevra-therapeutics-inc-zvra-guggenheim-securities-inaugural-healthcare-innovation-conferenc_oCqDlg0A", "source_name": "Quartr", "published_at": "2026-07-08T23:09:58", "published_display": "08 Jul 2026 23:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 ZEVRA THERAPEUTICS For: 8 July By Investing.com", "summary": "This article from Investing.com reports on a Form 144 filing for ZEVRA THERAPEUTICS on July 8. Form 144 filings indicate an intent to sell restricted securities. The brief notice provides no further details beyond the company and date.", "url": "https://ng.investing.com/news/stock-market-news/form-144-zevra-therapeutics-for-8-july-93CH-2591954", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T22:34:00", "published_display": "08 Jul 2026 22:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] ZEVRA THERAPEUTICS, INC. SEC Filing", "summary": "This SEC filing (Form 144) for ZEVRA THERAPEUTICS, INC. details a proposed sale of 10,516 common shares with an aggregate market value of $156,162.60 by an executive. The shares were acquired on July 8, 2026, through a stock option exercise, with payment made in cash. The filing ", "url": "https://www.stocktitan.net/sec-filings/ZVRA/144-zevra-therapeutics-inc-sec-filing-2f2e3ef570d0.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:09:46", "published_display": "08 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZEVRA THERAPEUTICS, INC. SEC Filing (Jul 8, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxORWdiUEJneDBhNTVlR1VfSVdmaFR4bzlZdm56dks2NXViMEJQMDhmZVdrNm5NNHlhZkZkQml3bGdPRHZ3WlNJM0J4dXZNNWk1NWgyZHN2ZzNIeS03NjlvbEhKdW1LZVRXSXhuNlFKZ3BZTFJ1a0ZYREJ2dDd4MGVlbFQzamlDVVJBOUtQa21tQTRDZGRPQV9veVJLclVGbUF1?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Zevra Therapeutics (ZVRA) Blending Niche Rare-Disease Focus With Mainstream Index Visibility Effectively?", "summary": "Zevra Therapeutics (ZVRA) was recently added to several Russell indices, increasing its visibility to institutional investors. This comes as the company also published new clinical data for its Niemann-Pick disease type C therapy, MIPLYFFA, in pediatric patients. The article sugg", "url": "https://www.sahmcapital.com/news/content/is-zevra-therapeutics-zvra-blending-niche-rare-disease-focus-with-mainstream-index-visibility-effectively-2026-07-01", "source_name": "Sahm", "published_at": "2026-07-03T09:40:36", "published_display": "03 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $27", "summary": "BTIG has reiterated its Buy rating on Zevra Therapeutics (ZVRA.US) and maintained a target price of $27. This continued endorsement suggests confidence in the company's future prospects.", "url": "https://www.moomoo.com/news/post/72333357/btig-maintains-zevra-therapeutics-zvraus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-02T21:41:45", "published_display": "02 Jul 2026 21:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(ZVRA) Risk Channels and Responsive Allocation", "summary": "The article provides an AI-generated analysis of Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting strong near and mid-term sentiment that could extend long-term, with no clear price positioning signal or resistance levels above the current price. It offers three distinct inst", "url": "https://news.stocktradersdaily.com/news_release/21/ZVRA_Risk_Channels_and_Responsive_Allocation_070226123202_1782966722.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T00:11:01", "published_display": "02 Jul 2026 00:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZVRA - Zevra Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings information for Zevra Therapeutics Inc. (ZVRA), including its last closing price, market capitalization, key financial ratios, stock performance metrics, and analyst recommendations. It presents a comprehensive overview of the company'", "url": "https://finviz.com/stock?t=ZVRA&ta=1&p=w&ty=lf&page=3", "source_name": "Finviz", "published_at": "2026-07-01T12:10:10", "published_display": "01 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Zevra Therapeutics, Inc. \u2013 NASDAQ:ZVRA", "summary": "This article is a financial data page from TradingView focusing on Zevra Therapeutics, Inc. (NASDAQ: ZVRA). It provides an overview of the company's financial data, specifically its enterprise value to revenue forward metric. The page includes general market information and links", "url": "https://www.tradingview.com/symbols/NASDAQ-ZVRA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T07:39:42", "published_display": "30 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZVRA - Zevra Therapeutics Inc Dividends", "summary": "This article provides detailed financial and stock performance data for Zevra Therapeutics Inc (ZVRA). It lists key metrics such as market capitalization, income, sales, price-to-earnings ratio, various growth rates, and insider/institutional ownership percentages. The data indic", "url": "https://finviz.com/stock?t=ZVRA&ta=1&p=m&ty=dv&r=y5", "source_name": "Finviz", "published_at": "2026-06-29T19:39:56", "published_display": "29 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to Russell 2000 Value Benchmark", "summary": "Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) has been added to the Russell 2000 Value Benchmark, indicating its inclusion in this significant index. This update highlights the company's growing presence in the financial markets and follows other recent inclusions in related Russell i", "url": "https://www.marketscreener.com/news/zevra-therapeutics-inc-nasdaqgs-zvra-added-to-russell-2000-value-benchmark-ce7f5fdfd888f020", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:08:00", "published_display": "29 Jun 2026 11:08", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to Russell Microcap Value Benchmark Index", "summary": "Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) has been added to the Russell Microcap Value Benchmark Index. This inclusion is part of a series of recent additions to various Russell indexes, including the Russell 2000 Value Benchmark and Russell 3000 Value Benchmark. The company is a ", "url": "https://www.marketscreener.com/news/zevra-therapeutics-inc-nasdaqgs-zvra-added-to-russell-microcap-value-benchmark-index-ce7f5fded080f021", "source_name": "marketscreener.com", "published_at": "2026-06-29T09:26:00", "published_display": "29 Jun 2026 09:26", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 3000E Value Benchmark", "summary": "Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has been added to the Russell 3000E Value Benchmark, effective June 28, 2026. The company, a commercial-stage rare disease firm, also saw its shares added to several other Russell indices, including the Russell 2000 Value and Microcap Val", "url": "https://www.marketscreener.com/news/zevra-therapeutics-inc-nasdaqgs-zvra-added-to-russell-3000e-value-benchmark-ce7f5fddda8bf225", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:40:46", "published_display": "29 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 2000 Value-Defensive Index", "summary": "Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has been added to the Russell 2000 Value-Defensive Index. This announcement highlights the company's progress and recognition within the financial markets. Zevra Therapeutics is a commercial-stage rare disease company focusing on developi", "url": "https://www.marketscreener.com/news/zevra-therapeutics-inc-nasdaqgs-zvra-added-to-russell-2000-value-defensive-index-ce7f5fdedb8cf72c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T03:10:27", "published_display": "29 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Zevra Therapeutics, Inc. \u2013 DUS:1GDA", "summary": "This article provides financial information for Zevra Therapeutics, Inc. (DUS:1GDA) on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-book ratio. The content appears to be a stub or a section of a larger financial data display, indicating no trades a", "url": "https://www.tradingview.com/symbols/DUS-1GDA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T22:10:27", "published_display": "28 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Zevra Therapeutics, Inc. \u2013 NASDAQ:ZVRA", "summary": "This article provides financial information for Zevra Therapeutics, Inc. (NASDAQ: ZVRA), specifically focusing on its price to sales forward metric. The content highlights the company's financial overview within the pharmaceuticals sector, as presented on TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-ZVRA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T21:10:27", "published_display": "28 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Zevra Therapeutics, Inc. \u2013 DUS:1GDA", "summary": "This article provides financial information for Zevra Therapeutics, Inc. (DUS:1GDA), specifically focusing on its enterprise value to EBITDA forward metric. The content highlights the company's financial data on the Dusseldorf Stock Exchange as presented on TradingView.", "url": "https://www.tradingview.com/symbols/DUS-1GDA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:09:02", "published_display": "28 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics, Inc. Actuals & Estimates (SWB:1GDA)", "summary": "This article provides financial actuals and estimates for Zevra Therapeutics, Inc. (SWB:1GDA), including income statement, balance sheet, and cash flow data, alongside analyst forecasts. It details the company's past earnings performance, revenue figures, and upcoming earnings re", "url": "https://www.tradingview.com/symbols/SWB-1GDA/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-27T07:09:43", "published_display": "27 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics, Inc. Actuals & Estimates (TRADEGATE:1GDA)", "summary": "This article provides an overview of Zevra Therapeutics, Inc. (TRADEGATE:1GDA) stock, including financial actuals, analyst estimates, and key performance indicators. It covers projected price targets, historical stock prices, upcoming earnings dates, recent earnings and revenue f", "url": "https://www.tradingview.com/symbols/TRADEGATE-1GDA/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T21:09:17", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics, Inc. Actuals & Estimates (NASDAQ:ZVRA)", "summary": "This article provides an overview of Zevra Therapeutics, Inc. (ZVRA) stock performance, financials, and analyst forecasts. It covers recent price changes, historical highs and lows, market capitalization, upcoming earnings reports, and revenue details, along with analyst predicti", "url": "https://www.tradingview.com/symbols/NASDAQ-ZVRA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T23:40:27", "published_display": "25 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "1GDA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Zevra Therapeutics, Inc. (1GDA) stock, including analyst price targets, historical highs and lows, and upcoming earnings information. Analysts have given a max estimate of 30.34 EUR and a min estimate of 18.20 EUR for the stock's future price.", "url": "https://www.tradingview.com/symbols/DUS-1GDA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:26", "published_display": "25 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics Announces Publication of Positive MIPLYFFA\u00ae Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/zevra-therapeutics-announces-publication-positive-113000274.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T11:30:00+00:00", "published_display": "23 Jun 2026 11:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics (ZVRA) legal chief sells shares after RSU exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQRnUxVEUzbF8tNGg4VTVLVHgtQWRneS1rVDY1ME9KdXFWYTgxM2Q1eGJ3WmFrVUNyaUFRY0ZwT3U2V25xaW9UWWhCdENtV3FYNVZ0Q2dMdjI0S1N5dzE4QjZiX09kTzhxUVZmeWFDVzZnck05aWIxcElNelQ2NlFndktsME5pVkVQVzk1Z2lSZ0ZJYW1zMTNXSzh5WXpPbk9SMExJa25hbmhBMTJkSnFDZlRaMjhqLXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Board member at Zevra (NASDAQ: ZVRA) receives 30,000-share option grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQUy1pQkhGNkRSU1N3Z3V0WmNEZlNGM0hJaDJjYV9RLXRTUWh6b3VlZEQxZFQxT0QtN2t0M1dUUFJDLXFqaEFBWkNYVjZlMXVrUUY5aTFGQTZNaktWbTlpME05RGtrVlVaREQ5WHl6eVVRSEJGZGQ4bVIwbDFVNU9ZOXNIZjlUUTBPS25TcE41LVUxLUlTZVYwbTRsQklTMl80RzYzZ3JDOWVxSEpaMkM4MUNtSXNnY3M?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics (ZVRA) awards director 30,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNWXVmeFZPZzBHQW9LQkx2Ym1ZWHU2Mmg4Tmt6ZHZyUVRrZjk4d1JVYUpCQTNfTGRUUFQzRVFuYmRpdUhaRnpyb3c5M09MaEE0b1pfVDdqNTh2QzV3bERRdlF2T2Qtc1pTckEyVzhZSWdIVjNXRjlmMmxPVVdXclFJTFhvaWQ2SmRWT2R1UGl5X1VpdHVBb2E1elFkNzE4b0tNMnV5WGJxVk1yMTZlbkxMalpkVGYtLW8?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZVRA Stock Price and Chart \u2014 NASDAQ:ZVRA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9FUmhSamRYd2ZKa0pIT0UtYWY0NEhpVEZFMkhoR2dHRDJnZ0J5QzUyeDl6aWxiTjI3eFJKSndXWGNhM0NnU2tzQTlwbldJR181VFQweUg0b0tVdUV5?oc=5", "source_name": "TradingView", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra\u2019s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/zevra-chief-medical-officer-step-123000909.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T12:30:00+00:00", "published_display": "11 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZjJDYTl0WGw4WGhCbDhOOXY2R2hQajM0NGQxUk8yZmFlYmNqTG5wU1VESFYtRWNLRTNiQkdwazNYQUpkaTctM0Y1aTVDWlpXZTViaUJSWmZsT3cxX2VYdEE1VWFRZWhaWkwzQlZMSFMwUE1BYmVFODVqYzhJWktTM0lQN183c1FjRGlXcWRvNjRrVlVtUTBJT25WTmJ6N2ZVVGZlVzJ5d3l3TEk?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics extends MIPLYFFA exclusivity to 2041", "summary": "", "url": "https://finance.yahoo.com/m/00792aa0-61c2-3adb-82c4-83b02de2f405/zevra-therapeutics-extends.html", "source_name": "Proactive", "published_at": "2026-06-08T16:25:00+00:00", "published_display": "08 Jun 2026 16:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/zevra-therapeutics-announces-orange-book-113000795.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T11:30:00+00:00", "published_display": "08 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/zevra-therapeutics-announces-inducement-grants-203000404.html", "source_name": "GlobeNewswire", "published_at": "2026-05-29T20:30:00+00:00", "published_display": "29 May 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZVRA - Zevra Therapeutics Inc Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTE5TTGFuRGVoYVd1QlNXcm1nWVJhZHNEbVJkUXpfVWxYcnQ3OEZPS0ZyUWZCd0JkT0xvVGtrRnl5Y09JZkQ5R3c?oc=5", "source_name": "Finviz", "published_at": "2026-05-26T13:23:59+00:00", "published_display": "26 May 2026 13:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Zevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They Appear", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOdWNldldiQld4MERaY2F1NmdiVFQyYm5FNUhMNEFvV0hPWVhhWEloLWozR3d5dlFVZjBvYzMwcms0M2ttQ3I5Rkl5Mm8yNlFBU3NENU05RU1FM1o2TmdXX0RGQUdPdTFwTmpjVGVxcGRudnRmNW10d3c3eWR1VDN6Z2xkQy14NUJXNVpld3Zn?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Zevra Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPTFNUODJOZ1JNdDRVQl8tcHRkdWNlbDRXUV9UUy0ycXl1ZXlHdFY2WVBnYkFqMEZJYWFqUEpWbVBlQ2dyZnhsRklJVHZ4R0E5Ukh3M1RvYzc1dXFzLU5DaXhaSFlwT3FWZmhTZWpZY0pZZnhLOV9Rb3JGUzQ0MEFnYmJZOWVyLWloNGtyQ3Jiak5mcFNwRnhPanZmNC0tUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOWGdMS0FrQzVmM080eUhmY3RIUTJ5eDhCNk1BMDlvTDlYQWRxSDlBV3IwWTRzS0FzRERjTEg1RGFkd0hBaXhOYXFMN285eDRPd2JpUFB2ZG4xWUZnX0t0U2NJS0hSTFZ5SjNqc2VKejBfcklRNTdkVnVqYThKV283S2hyX3hnQnFRN1FyazUtNFpQOFVhY3BTbEFuNkJzRlFQUlBr?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC reports 3.21M-share stake in Zevra Therapeutics (NASDAQ: ZVRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPTXpxM0NickhWbEp6T2FGV3NhNlN0SGcyTXFTZ2l2WlRWMUlMM3lDa1pxYWxBQ2pLYWRQMXJvelB4dXVXUlpJU3Vpbml2TWdXTFB5dXpSTHpwSkZGbDdjLWVsR3kxX3A4cmlyNlh3VEVVSVhZM1hUNHNHeXNvT1B5dDlGcWN5YkFzbm1rdk9kblRlckxuMHpTMTZ6QUJRS2Q3SWRuLWh2M0F2MG9PLTA2eVZ2OVVaUkNJeTZmd1ZBRWN1MXkzTGNSRg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOdnowSHRvajdWY2l6aWpMVHQzMWJSRVdYcDdOc2gxdTc3RV9Ea2JxYWpuSnFoQ3BUcW5MUzJPbk5TT2psLVNwWlhWV2hESDllcmdpMFp3c3NVTUs3OFdXZHVFY2l4TUkxMDRmVE5yZ1BGdk5QUFlWbU1oZGpydVVwSnh6dWNCV2p3dy0teFV4STJfcWlUTXJfUERBM3g0RTk3TXBRbTFHdw?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Zevra Therapeutics (ZVRA) Pricing Reflecting Its Strong Multi\u2011Year Share Price Performance", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNZU9EMkEtRF9LcnVIbHJSYXRRNW9LWGp6SDM0blhFVEZGN0J5bzl0dkw2SmszTjRCc0txSVhIVXlibzM5c3dPWElrbGJEaW1JbXZHZEhvT2ZNclNaY2R6MWJGSVI5SGIydDhnRzNrS2Joall0WGszXzd1U2pqNEVYVm00X0o4SjJ3eUd0cDQ5NDNRdw?oc=5", "source_name": "Market source", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics Stock Pre-Market (+17%): Reports Massive Q4 EPS Beat", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNUUZtUU5MbW1URkZkVENCYXBHd25mZ0FYX2g1T0hHc296RVZWUHZ1Q2prWDJHRHlfMmhFMUx2amk2SzNKbHI2eHI5VHhObkRmN2N5UUV0Slo2WW1XTzhpeURGbkZISFV5RGduaEFlR2trSV9BWjZQY2hlaWh1T3ZFbzhxaTEySzJ4alk5bWx3bnhEUGpBdEZPRmZNalR6cndJZDRWbXpzZG5CWHVQVGhxeWpYb3RZc01IRTlvZ0hNdmh4R0ZrY1phM3NIcHRhMXd5eUE?oc=5", "source_name": "Trefis", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model (NASDAQ:ZVRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOYk5Ea3NXSS00cVpwUGRqUTJHMlVoMmJRUURlMkJqRVJxT29BcFZfSFFMUzF0bDZ2LXM5TmY5bVU1M09hWnl0YjUxZFpCZGtwNGV3M0E3RUIxLU1PdWNmX0haYkJlVmNGdUd3bHFHajg4bHpVRHBaMWI1UTViN3I5RkIzLU5Rb1RNd3oyd3FlZnNVLUVJUGluOGF1SE5ldld3ZXBManpCTkwxSUlNTUotZUw5aU5Gdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQdDVVbmxMQm5heWNiYzE5bllGVGxaYTk2RmN4cFFCRkluY3pGa2RZTHNHY0pSRU5TQnAxMzlzQm03V25Lc2o5NVZVMEZMUmRZb21SLThDdGI5Rm1ZVnpBLTJNUEE4bjFwcVZKeVhjQmNscDI5S2VmR0JvMVZSNkg1d3JES3d6ZnZ6ODhtcHRVNG1WWHUybG00dVZ0ZG1RUFZWMTQwWHhyajM0N3BKdWd0UU14SjVSN0xGQXFVV3NqMXU?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-03T08:00:00+00:00", "published_display": "03 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-08T08:00:00+00:00", "published_display": "08 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics (NASDAQ:ZVRA) Is Using Debt Safely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-03T08:00:00+00:00", "published_display": "03 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What You Can Learn From Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) P/S After Its 26% Share Price Crash", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQNzByN21YTXA1SzJqY3JEOWwwS1pIYWVncmcwekxqcGRSODRfSmp2SzlzWjJGWVI5RWtLMHFqNy1qWjdIVDB6NmJqVTlyQ2dqMXhtZ1dtUFlweFB6bWxEWGtiV0Jwd25YbndoY0xiczhDb1psWEpSNDJDUVgwNjVyODV3c1h2aFA4MC1ZZkEwLU96c0hfMzlFWHBZcXhlckN1QXQ3LUd0UFkzbDlEZ0tSOVd1SlNCS1pkSXR4a1N2anlzelhRUkVmQWZJZl90bTdWVzNmd2trWE5CdE5PRzhoNlRWVG8xRTDSAewBQVVfeXFMUHJjYzZ2S1BWaUg1OXV5TGFzdEFOUm0tVzJtUmtnOUdzUUVRSUhpazh4RjRaTXg1RjA5QXhWWmRPYkNYWEpCRl9GLUpONDRzaFliQUozeEhEbG5IZFdjVGlfcWUySXV3STZ5LUhrUFNmc0FNT0pDQTluUHJ3czN6Rk45cVlGaElKWndsSF9lVG9CVmFvZWhhNGktVGlOWGU1LUpGNnNFTlhXZ01uczlMVERGNDY2akNNQjNMQlEyMmV1eDdJTUZEaDBqbUJJcG56LUtUUlY3UFdZWl95UTRBUVp2TU16MENwNkZJbEg?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-08T07:00:00+00:00", "published_display": "08 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call", "summary": "Zevra Therapeutics announced it will report its second-quarter 2026 corporate and financial results on Wednesday, August 5, 2026, via a news release after market close. The company will also host a conference call and audio webcast at 4:30 p.m. ET on the same day. Details for acc", "url": "https://www.manilatimes.net/2026/07/22/tmt-newswire/globenewswire/zevra-therapeutics-announces-details-for-q2-2026-financial-results-call/2389262/amp", "source_name": "The Manila Times", "published_at": "2026-07-22T11:40:00", "published_display": "22 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra\u2019s Aug. 5 results webcast will be replayed for 90 days", "summary": "Zevra Therapeutics (NasdaqGS: ZVRA) announced it will release its Q2 2026 corporate and financial results on Wednesday, August 5, 2026, after market close, followed by a conference call and audio webcast at 4:30 p.m. ET. A replay of the webcast will be available for 90 days on th", "url": "https://www.stocktitan.net/news/ZVRA/zevra-therapeutics-announces-details-for-q2-2026-financial-results-600bgnmt0b0w.html", "source_name": "Stock Titan", "published_at": "2026-07-22T11:40:00", "published_display": "22 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics Announces Date for Second Quarter 2026 Financial Results Conference Call", "summary": "Zevra Therapeutics announced it will release its second quarter 2026 corporate and financial results on August 5, 2026, followed by a conference call and audio webcast at 4:30 p.m. ET. The company, which focuses on developing therapies for rare diseases, highlighted its commitmen", "url": "https://www.quiverquant.com/news/Zevra+Therapeutics+Announces+Date+for+Second+Quarter+2026+Financial+Results+Conference+Call", "source_name": "Quiver Quantitative", "published_at": "2026-07-22T11:40:00", "published_display": "22 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZVRA - Zevra Therapeutics: Galloping Through a Green Safari", "summary": "Zevra Therapeutics has successfully transitioned from a prodrug company to a rare disease powerhouse, marked by the FDA approval of MIPLYFFA for Niemann-Pick disease Type C and a $100 million sale of a Rare Pediatric Disease Priority Review Voucher. The company's financial standi", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-zvra/zevra-therapeutics/a4vhnswa-zevra-therapeutics-galloping-through-a-green-safari", "source_name": "Simply Wall Street", "published_at": "2026-07-20T15:11:30", "published_display": "20 Jul 2026 15:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(ZVRA) as a Liquidity Pulse for Institutional Tactics", "summary": "This article provides an AI-driven analysis of Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting conflicting sentiment across different time horizons and suggesting potential choppy conditions. It presents three institutional trading strategies\u2014Position Trading, Momentum Break", "url": "https://news.stocktradersdaily.com/news_release/17/ZVRA_as_a_Liquidity_Pulse_for_Institutional_Tactics_071326014002_1783921202.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T01:40:00", "published_display": "13 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Zevra\u2019s Broad Russell Index Inclusion Reshaping the Investment Case for Zevra Therapeutics (ZVRA)?", "summary": "Zevra Therapeutics (ZVRA) has been added to several Russell indexes, including the Russell 2000 Value, increasing its visibility among institutional investors. While this inclusion may boost liquidity and trading support, it doesn't alter the fundamental product or regulatory ris", "url": "https://www.sahmcapital.com/news/content/is-zevras-broad-russell-index-inclusion-reshaping-the-investment-case-for-zevra-therapeutics-zvra-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T00:09:28", "published_display": "11 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics (ZVRA) Q4 2024 earnings summary", "summary": "Zevra Therapeutics (ZVRA) reported its Q4 2024 earnings, highlighting its transition to a commercial-stage company with the FDA approval and launch of Miplyffa for Niemann-Pick disease type C. The company achieved $23.6M in net revenue for FY 2024, driven by Miplyffa and OLPRUVA ", "url": "https://quartr.com/events/zevra-therapeutics-zvra-q4-2024_oCqDlg9E", "source_name": "Quartr", "published_at": "2026-07-10T12:12:06", "published_display": "10 Jul 2026 12:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics (ZVRA) Guggenheim Securities Inaugural Healthcare Innovation Conference summary", "summary": "Zevra Therapeutics (ZVRA) presented at the Guggenheim Securities Inaugural Healthcare Innovation Conference, highlighting its rare disease focus, two marketed products (MIPLYFFA and OLPRUVA), and late-stage development programs. The company discussed its commercial launch strateg", "url": "https://quartr.com/events/zevra-therapeutics-inc-zvra-guggenheim-securities-inaugural-healthcare-innovation-conferenc_oCqDlg0A", "source_name": "Quartr", "published_at": "2026-07-08T23:09:58", "published_display": "08 Jul 2026 23:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 ZEVRA THERAPEUTICS For: 8 July By Investing.com", "summary": "This article from Investing.com reports on a Form 144 filing for ZEVRA THERAPEUTICS on July 8. Form 144 filings indicate an intent to sell restricted securities. The brief notice provides no further details beyond the company and date.", "url": "https://ng.investing.com/news/stock-market-news/form-144-zevra-therapeutics-for-8-july-93CH-2591954", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T22:34:00", "published_display": "08 Jul 2026 22:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] ZEVRA THERAPEUTICS, INC. SEC Filing", "summary": "This SEC filing (Form 144) for ZEVRA THERAPEUTICS, INC. details a proposed sale of 10,516 common shares with an aggregate market value of $156,162.60 by an executive. The shares were acquired on July 8, 2026, through a stock option exercise, with payment made in cash. The filing ", "url": "https://www.stocktitan.net/sec-filings/ZVRA/144-zevra-therapeutics-inc-sec-filing-2f2e3ef570d0.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:09:46", "published_display": "08 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZEVRA THERAPEUTICS, INC. SEC Filing (Jul 8, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxORWdiUEJneDBhNTVlR1VfSVdmaFR4bzlZdm56dks2NXViMEJQMDhmZVdrNm5NNHlhZkZkQml3bGdPRHZ3WlNJM0J4dXZNNWk1NWgyZHN2ZzNIeS03NjlvbEhKdW1LZVRXSXhuNlFKZ3BZTFJ1a0ZYREJ2dDd4MGVlbFQzamlDVVJBOUtQa21tQTRDZGRPQV9veVJLclVGbUF1?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Zevra Therapeutics (ZVRA) Blending Niche Rare-Disease Focus With Mainstream Index Visibility Effectively?", "summary": "Zevra Therapeutics (ZVRA) was recently added to several Russell indices, increasing its visibility to institutional investors. This comes as the company also published new clinical data for its Niemann-Pick disease type C therapy, MIPLYFFA, in pediatric patients. The article sugg", "url": "https://www.sahmcapital.com/news/content/is-zevra-therapeutics-zvra-blending-niche-rare-disease-focus-with-mainstream-index-visibility-effectively-2026-07-01", "source_name": "Sahm", "published_at": "2026-07-03T09:40:36", "published_display": "03 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $27", "summary": "BTIG has reiterated its Buy rating on Zevra Therapeutics (ZVRA.US) and maintained a target price of $27. This continued endorsement suggests confidence in the company's future prospects.", "url": "https://www.moomoo.com/news/post/72333357/btig-maintains-zevra-therapeutics-zvraus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-02T21:41:45", "published_display": "02 Jul 2026 21:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(ZVRA) Risk Channels and Responsive Allocation", "summary": "The article provides an AI-generated analysis of Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting strong near and mid-term sentiment that could extend long-term, with no clear price positioning signal or resistance levels above the current price. It offers three distinct inst", "url": "https://news.stocktradersdaily.com/news_release/21/ZVRA_Risk_Channels_and_Responsive_Allocation_070226123202_1782966722.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T00:11:01", "published_display": "02 Jul 2026 00:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZVRA - Zevra Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings information for Zevra Therapeutics Inc. (ZVRA), including its last closing price, market capitalization, key financial ratios, stock performance metrics, and analyst recommendations. It presents a comprehensive overview of the company'", "url": "https://finviz.com/stock?t=ZVRA&ta=1&p=w&ty=lf&page=3", "source_name": "Finviz", "published_at": "2026-07-01T12:10:10", "published_display": "01 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Zevra Therapeutics, Inc. \u2013 NASDAQ:ZVRA", "summary": "This article is a financial data page from TradingView focusing on Zevra Therapeutics, Inc. (NASDAQ: ZVRA). It provides an overview of the company's financial data, specifically its enterprise value to revenue forward metric. The page includes general market information and links", "url": "https://www.tradingview.com/symbols/NASDAQ-ZVRA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T07:39:42", "published_display": "30 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZVRA - Zevra Therapeutics Inc Dividends", "summary": "This article provides detailed financial and stock performance data for Zevra Therapeutics Inc (ZVRA). It lists key metrics such as market capitalization, income, sales, price-to-earnings ratio, various growth rates, and insider/institutional ownership percentages. The data indic", "url": "https://finviz.com/stock?t=ZVRA&ta=1&p=m&ty=dv&r=y5", "source_name": "Finviz", "published_at": "2026-06-29T19:39:56", "published_display": "29 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to Russell 2000 Value Benchmark", "summary": "Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) has been added to the Russell 2000 Value Benchmark, indicating its inclusion in this significant index. This update highlights the company's growing presence in the financial markets and follows other recent inclusions in related Russell i", "url": "https://www.marketscreener.com/news/zevra-therapeutics-inc-nasdaqgs-zvra-added-to-russell-2000-value-benchmark-ce7f5fdfd888f020", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:08:00", "published_display": "29 Jun 2026 11:08", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to Russell Microcap Value Benchmark Index", "summary": "Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) has been added to the Russell Microcap Value Benchmark Index. This inclusion is part of a series of recent additions to various Russell indexes, including the Russell 2000 Value Benchmark and Russell 3000 Value Benchmark. The company is a ", "url": "https://www.marketscreener.com/news/zevra-therapeutics-inc-nasdaqgs-zvra-added-to-russell-microcap-value-benchmark-index-ce7f5fded080f021", "source_name": "marketscreener.com", "published_at": "2026-06-29T09:26:00", "published_display": "29 Jun 2026 09:26", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 3000E Value Benchmark", "summary": "Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has been added to the Russell 3000E Value Benchmark, effective June 28, 2026. The company, a commercial-stage rare disease firm, also saw its shares added to several other Russell indices, including the Russell 2000 Value and Microcap Val", "url": "https://www.marketscreener.com/news/zevra-therapeutics-inc-nasdaqgs-zvra-added-to-russell-3000e-value-benchmark-ce7f5fddda8bf225", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:40:46", "published_display": "29 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 2000 Value-Defensive Index", "summary": "Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has been added to the Russell 2000 Value-Defensive Index. This announcement highlights the company's progress and recognition within the financial markets. Zevra Therapeutics is a commercial-stage rare disease company focusing on developi", "url": "https://www.marketscreener.com/news/zevra-therapeutics-inc-nasdaqgs-zvra-added-to-russell-2000-value-defensive-index-ce7f5fdedb8cf72c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T03:10:27", "published_display": "29 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Zevra Therapeutics, Inc. \u2013 DUS:1GDA", "summary": "This article provides financial information for Zevra Therapeutics, Inc. (DUS:1GDA) on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-book ratio. The content appears to be a stub or a section of a larger financial data display, indicating no trades a", "url": "https://www.tradingview.com/symbols/DUS-1GDA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T22:10:27", "published_display": "28 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Zevra Therapeutics, Inc. \u2013 NASDAQ:ZVRA", "summary": "This article provides financial information for Zevra Therapeutics, Inc. (NASDAQ: ZVRA), specifically focusing on its price to sales forward metric. The content highlights the company's financial overview within the pharmaceuticals sector, as presented on TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-ZVRA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T21:10:27", "published_display": "28 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Zevra Therapeutics, Inc. \u2013 DUS:1GDA", "summary": "This article provides financial information for Zevra Therapeutics, Inc. (DUS:1GDA), specifically focusing on its enterprise value to EBITDA forward metric. The content highlights the company's financial data on the Dusseldorf Stock Exchange as presented on TradingView.", "url": "https://www.tradingview.com/symbols/DUS-1GDA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:09:02", "published_display": "28 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics, Inc. Actuals & Estimates (SWB:1GDA)", "summary": "This article provides financial actuals and estimates for Zevra Therapeutics, Inc. (SWB:1GDA), including income statement, balance sheet, and cash flow data, alongside analyst forecasts. It details the company's past earnings performance, revenue figures, and upcoming earnings re", "url": "https://www.tradingview.com/symbols/SWB-1GDA/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-27T07:09:43", "published_display": "27 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics, Inc. Actuals & Estimates (TRADEGATE:1GDA)", "summary": "This article provides an overview of Zevra Therapeutics, Inc. (TRADEGATE:1GDA) stock, including financial actuals, analyst estimates, and key performance indicators. It covers projected price targets, historical stock prices, upcoming earnings dates, recent earnings and revenue f", "url": "https://www.tradingview.com/symbols/TRADEGATE-1GDA/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T21:09:17", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics, Inc. Actuals & Estimates (NASDAQ:ZVRA)", "summary": "This article provides an overview of Zevra Therapeutics, Inc. (ZVRA) stock performance, financials, and analyst forecasts. It covers recent price changes, historical highs and lows, market capitalization, upcoming earnings reports, and revenue details, along with analyst predicti", "url": "https://www.tradingview.com/symbols/NASDAQ-ZVRA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T23:40:27", "published_display": "25 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "1GDA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Zevra Therapeutics, Inc. (1GDA) stock, including analyst price targets, historical highs and lows, and upcoming earnings information. Analysts have given a max estimate of 30.34 EUR and a min estimate of 18.20 EUR for the stock's future price.", "url": "https://www.tradingview.com/symbols/DUS-1GDA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:26", "published_display": "25 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics Announces Publication of Positive MIPLYFFA\u00ae Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/zevra-therapeutics-announces-publication-positive-113000274.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T11:30:00+00:00", "published_display": "23 Jun 2026 11:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics (ZVRA) legal chief sells shares after RSU exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQRnUxVEUzbF8tNGg4VTVLVHgtQWRneS1rVDY1ME9KdXFWYTgxM2Q1eGJ3WmFrVUNyaUFRY0ZwT3U2V25xaW9UWWhCdENtV3FYNVZ0Q2dMdjI0S1N5dzE4QjZiX09kTzhxUVZmeWFDVzZnck05aWIxcElNelQ2NlFndktsME5pVkVQVzk1Z2lSZ0ZJYW1zMTNXSzh5WXpPbk9SMExJa25hbmhBMTJkSnFDZlRaMjhqLXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Board member at Zevra (NASDAQ: ZVRA) receives 30,000-share option grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQUy1pQkhGNkRSU1N3Z3V0WmNEZlNGM0hJaDJjYV9RLXRTUWh6b3VlZEQxZFQxT0QtN2t0M1dUUFJDLXFqaEFBWkNYVjZlMXVrUUY5aTFGQTZNaktWbTlpME05RGtrVlVaREQ5WHl6eVVRSEJGZGQ4bVIwbDFVNU9ZOXNIZjlUUTBPS25TcE41LVUxLUlTZVYwbTRsQklTMl80RzYzZ3JDOWVxSEpaMkM4MUNtSXNnY3M?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics (ZVRA) awards director 30,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNWXVmeFZPZzBHQW9LQkx2Ym1ZWHU2Mmg4Tmt6ZHZyUVRrZjk4d1JVYUpCQTNfTGRUUFQzRVFuYmRpdUhaRnpyb3c5M09MaEE0b1pfVDdqNTh2QzV3bERRdlF2T2Qtc1pTckEyVzhZSWdIVjNXRjlmMmxPVVdXclFJTFhvaWQ2SmRWT2R1UGl5X1VpdHVBb2E1elFkNzE4b0tNMnV5WGJxVk1yMTZlbkxMalpkVGYtLW8?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZVRA Stock Price and Chart \u2014 NASDAQ:ZVRA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9FUmhSamRYd2ZKa0pIT0UtYWY0NEhpVEZFMkhoR2dHRDJnZ0J5QzUyeDl6aWxiTjI3eFJKSndXWGNhM0NnU2tzQTlwbldJR181VFQweUg0b0tVdUV5?oc=5", "source_name": "TradingView", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra\u2019s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/zevra-chief-medical-officer-step-123000909.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T12:30:00+00:00", "published_display": "11 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZjJDYTl0WGw4WGhCbDhOOXY2R2hQajM0NGQxUk8yZmFlYmNqTG5wU1VESFYtRWNLRTNiQkdwazNYQUpkaTctM0Y1aTVDWlpXZTViaUJSWmZsT3cxX2VYdEE1VWFRZWhaWkwzQlZMSFMwUE1BYmVFODVqYzhJWktTM0lQN183c1FjRGlXcWRvNjRrVlVtUTBJT25WTmJ6N2ZVVGZlVzJ5d3l3TEk?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics extends MIPLYFFA exclusivity to 2041", "summary": "", "url": "https://finance.yahoo.com/m/00792aa0-61c2-3adb-82c4-83b02de2f405/zevra-therapeutics-extends.html", "source_name": "Proactive", "published_at": "2026-06-08T16:25:00+00:00", "published_display": "08 Jun 2026 16:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/zevra-therapeutics-announces-orange-book-113000795.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T11:30:00+00:00", "published_display": "08 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/zevra-therapeutics-announces-inducement-grants-203000404.html", "source_name": "GlobeNewswire", "published_at": "2026-05-29T20:30:00+00:00", "published_display": "29 May 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZVRA - Zevra Therapeutics Inc Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTE5TTGFuRGVoYVd1QlNXcm1nWVJhZHNEbVJkUXpfVWxYcnQ3OEZPS0ZyUWZCd0JkT0xvVGtrRnl5Y09JZkQ5R3c?oc=5", "source_name": "Finviz", "published_at": "2026-05-26T13:23:59+00:00", "published_display": "26 May 2026 13:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They Appear", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOdWNldldiQld4MERaY2F1NmdiVFQyYm5FNUhMNEFvV0hPWVhhWEloLWozR3d5dlFVZjBvYzMwcms0M2ttQ3I5Rkl5Mm8yNlFBU3NENU05RU1FM1o2TmdXX0RGQUdPdTFwTmpjVGVxcGRudnRmNW10d3c3eWR1VDN6Z2xkQy14NUJXNVpld3Zn?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPTFNUODJOZ1JNdDRVQl8tcHRkdWNlbDRXUV9UUy0ycXl1ZXlHdFY2WVBnYkFqMEZJYWFqUEpWbVBlQ2dyZnhsRklJVHZ4R0E5Ukh3M1RvYzc1dXFzLU5DaXhaSFlwT3FWZmhTZWpZY0pZZnhLOV9Rb3JGUzQ0MEFnYmJZOWVyLWloNGtyQ3Jiak5mcFNwRnhPanZmNC0tUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOWGdMS0FrQzVmM080eUhmY3RIUTJ5eDhCNk1BMDlvTDlYQWRxSDlBV3IwWTRzS0FzRERjTEg1RGFkd0hBaXhOYXFMN285eDRPd2JpUFB2ZG4xWUZnX0t0U2NJS0hSTFZ5SjNqc2VKejBfcklRNTdkVnVqYThKV283S2hyX3hnQnFRN1FyazUtNFpQOFVhY3BTbEFuNkJzRlFQUlBr?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC reports 3.21M-share stake in Zevra Therapeutics (NASDAQ: ZVRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPTXpxM0NickhWbEp6T2FGV3NhNlN0SGcyTXFTZ2l2WlRWMUlMM3lDa1pxYWxBQ2pLYWRQMXJvelB4dXVXUlpJU3Vpbml2TWdXTFB5dXpSTHpwSkZGbDdjLWVsR3kxX3A4cmlyNlh3VEVVSVhZM1hUNHNHeXNvT1B5dDlGcWN5YkFzbm1rdk9kblRlckxuMHpTMTZ6QUJRS2Q3SWRuLWh2M0F2MG9PLTA2eVZ2OVVaUkNJeTZmd1ZBRWN1MXkzTGNSRg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOdnowSHRvajdWY2l6aWpMVHQzMWJSRVdYcDdOc2gxdTc3RV9Ea2JxYWpuSnFoQ3BUcW5MUzJPbk5TT2psLVNwWlhWV2hESDllcmdpMFp3c3NVTUs3OFdXZHVFY2l4TUkxMDRmVE5yZ1BGdk5QUFlWbU1oZGpydVVwSnh6dWNCV2p3dy0teFV4STJfcWlUTXJfUERBM3g0RTk3TXBRbTFHdw?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Zevra Therapeutics (ZVRA) Pricing Reflecting Its Strong Multi\u2011Year Share Price Performance", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNZU9EMkEtRF9LcnVIbHJSYXRRNW9LWGp6SDM0blhFVEZGN0J5bzl0dkw2SmszTjRCc0txSVhIVXlibzM5c3dPWElrbGJEaW1JbXZHZEhvT2ZNclNaY2R6MWJGSVI5SGIydDhnRzNrS2Joall0WGszXzd1U2pqNEVYVm00X0o4SjJ3eUd0cDQ5NDNRdw?oc=5", "source_name": "Market source", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics Stock Pre-Market (+17%): Reports Massive Q4 EPS Beat", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNUUZtUU5MbW1URkZkVENCYXBHd25mZ0FYX2g1T0hHc296RVZWUHZ1Q2prWDJHRHlfMmhFMUx2amk2SzNKbHI2eHI5VHhObkRmN2N5UUV0Slo2WW1XTzhpeURGbkZISFV5RGduaEFlR2trSV9BWjZQY2hlaWh1T3ZFbzhxaTEySzJ4alk5bWx3bnhEUGpBdEZPRmZNalR6cndJZDRWbXpzZG5CWHVQVGhxeWpYb3RZc01IRTlvZ0hNdmh4R0ZrY1phM3NIcHRhMXd5eUE?oc=5", "source_name": "Trefis", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model (NASDAQ:ZVRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOYk5Ea3NXSS00cVpwUGRqUTJHMlVoMmJRUURlMkJqRVJxT29BcFZfSFFMUzF0bDZ2LXM5TmY5bVU1M09hWnl0YjUxZFpCZGtwNGV3M0E3RUIxLU1PdWNmX0haYkJlVmNGdUd3bHFHajg4bHpVRHBaMWI1UTViN3I5RkIzLU5Rb1RNd3oyd3FlZnNVLUVJUGluOGF1SE5ldld3ZXBManpCTkwxSUlNTUotZUw5aU5Gdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQdDVVbmxMQm5heWNiYzE5bllGVGxaYTk2RmN4cFFCRkluY3pGa2RZTHNHY0pSRU5TQnAxMzlzQm03V25Lc2o5NVZVMEZMUmRZb21SLThDdGI5Rm1ZVnpBLTJNUEE4bjFwcVZKeVhjQmNscDI5S2VmR0JvMVZSNkg1d3JES3d6ZnZ6ODhtcHRVNG1WWHUybG00dVZ0ZG1RUFZWMTQwWHhyajM0N3BKdWd0UU14SjVSN0xGQXFVV3NqMXU?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-03T08:00:00+00:00", "published_display": "03 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-08T08:00:00+00:00", "published_display": "08 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zevra Therapeutics (NASDAQ:ZVRA) Is Using Debt Safely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-03T08:00:00+00:00", "published_display": "03 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What You Can Learn From Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) P/S After Its 26% Share Price Crash", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-08T07:00:00+00:00", "published_display": "08 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 61, "sentiment_summary": {"positive": 20, "negative": 1, "neutral": 40, "score": 57, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 17.2, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 10.31, "count": 21}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 20, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 12.77, "latest_week": "2026-07-17", "one_week_move": -4.3, "four_week_move": -1.0, "twelve_week_move": 26.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.168573, "market_dynamics_buy_signal": false, "relative_strength": 15.943576, "fair_value_gap": 64.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 44.6479, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.3% over one week, -1.0% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "TradingView", "count": 10}, {"label": "Stock Titan", "count": 7}, {"label": "simplywall.st", "count": 5}, {"label": "GlobeNewswire", "count": 4}, {"label": "Finviz", "count": 3}, {"label": "www.marketscreener.com", "count": 3}, {"label": "Stock Traders Daily", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 21}, {"label": "Balance sheet", "count": 3}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 2}, {"label": "Macro sensitivity", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-4.3% over one week, -1.0% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call"}], "updated_at": "2026-07-23T07:15:04.434158+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}